Phaseline

Targets › JAK2

JAK2 (Tyrosine-protein kinase JAK2): drug programs, companies and trials

24 programs from 23 companies in 246 trials: 109 Phase 2, 58 Phase 1, 56 Phase 3, 23 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.

Non-membrane spanning protein tyrosine kinase that phosphorylates type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Functionally, plays a pivotal role in signal transduction and is involved in various processes such as cell growth,…. (UniProt, O60674)

Open in Phaseline: the race on JAK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 4Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus …Jul 2027
EisaiFilgotinib Maleate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 4Ulcerative ColitisNov 2027
IncyteRuxolitinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) …Nov 2026
AbbVieUpadacitinib
Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
TYK2, JAK3, JAK2, JAK1Phase 3Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease …Nov 2026
LEO PharmaDelgocitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; VitiligoDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQ05105 Tablets (Rovadicitinib Tablets)
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr
JAK1, JAK2, ROCK2Phase 3Graft-versus-host Disease; Chronic Graft Versus Host Disease; MyelofibrosisDec 2026
Swedish Orphan BiovitrumPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 3Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia …Dec 2026
Pfizertofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Ulcerative ColitisMar 2027
Chengdu Zenitar Biomedical TechnologyFlonoltinib Maleate
JAK1/JAK2 inhibitor
JAK1, JAK2Phase 3MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV)May 2027
Sun Pharmaceutical IndustriesDeuruxolitinib Phosphate (CTP-543)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3Alopecia AreataMay 2027
AlfasigmaFilgotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 3Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis …Jun 2027
Eli LillyBaricitinib (LY3009104)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
JAK1, JAK2Phase 3Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis …Mar 2028
Suzhou Zelgen BiopharmaceuticalsJaktinib Hydrochloride Tablet
JAK inhibitor
JAK1, JAK2, JAK3Phase 3Atopic Dermatitis–
GSKMomelotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor
JAK1, JAK2, ACVR1Phase 2Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia …Dec 2026
M.D. Anderson Cancer CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia …Jan 2027
Fudan UniversitySHR-0302
JAK inhibitor
JAK1, JAK2, JAK3Phase 2Relapsed/Refractory Peripheral T Cell LymphomaFeb 2027
City of Hope Medical CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System NeoplasmMar 2027
TheradexPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 2Leukemia, Myelomonocytic, ChronicJul 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineIvarmacitinib
JAK inhibitor
JAK1, JAK2Phase 2Esophageal Squamous Cell CarcinomaDec 2028
Shixiu WuJAK Inhibitors
Janus kinase inhibitors
JAK1, JAK2, JAK3, TYK2Phase 2Immune Checkpoint Inhibitors (ICI)-Related Dermatitis–
Bristol-Myers SquibbFedratinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
FLT3, JAK2Phase 1Primary Myelofibrosis; Acute Myeloid LeukemiaNov 2026
AbbVieTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 1Healthy VolunteersDec 2026
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLY5830966
Type II JAK2 inhibitor
JAK2Phase 1Primary MyelofibrosisJun 2027
First Affiliated Hospital of Zhejiang UniversityGecacitinib (also known as Jaktinib)
JAK inhibitor
JAK1, JAK2, JAK3Phase 1Acute Graft Versus Host DiseaseDec 2027

Conditions

Myelofibrosis (10) Rheumatoid Arthritis (9) Primary Myelofibrosis (8) Atopic Dermatitis (7) Ulcerative Colitis (6) Acute Lymphoblastic Leukemia (6) Acute Myeloid Leukemia (5) Alopecia Areata (4) Rheumatoid Arthritis (RA (4) Vitiligo (4) Hidradenitis Suppurativa (4) Chronic Graft Versus Host Disease (3)

Modalities

small molecule (22), mixed (2)

Companies

AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Chia Tai Tianqing Pharmaceutical Group (1) Sun Pharmaceutical Industries (1) Alfasigma (1) Bristol-Myers Squibb (1) Takeda (1) Incyte (1) Chengdu Zenitar Biomedical Technology (1) Eli Lilly (1) LEO Pharma (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (1) GSK (1) Eisai (1) Swedish Orphan Biovitrum (1) Theradex (1) City of Hope Medical Center (1) Shixiu Wu (1) M.D. Anderson Cancer Center (1)

Related targets

JAK1 (20) JAK3 (15) TYK2 (12) FLT3 (3) ACVR1 (3) IRAK1 (2) ROCK2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.